Introduction: Febrile neutropenia (FN) represents a life-threatening complication in hematological malignancies. Its etiology is most often due to infections even though FN of other origins, such as tumor-related fever and non-infectious inflammation, should rapidly be ruled out. Initially, C-reactive protein and, more recently, procalcitonin (PCT) have been proposed as useful biomarkers for differential diagnosis. PCT was shown to be a good biomarker of bacterial infections and their clinical outcomes. Definition of standard cut-offs and design of PCT-guided treatment protocols remain however to be defined.Areas covered: In this review, highlights on the current clinical use of PCT and its potential role as a diagnostic tool have been discussed by a panel of physicians from different areas of expertise. We provide current clinical evidence that PCT has been shown to be a reliable biomarker to differentiate fever of bacterial origin from other causes. Moreover, the Authors convened to a round-table to discuss their real-life experience' and offer their recommendations by a Delphi survey.Expert commentary: PCT has an important clinical role in FN. Issues such as the validation of a specific decision algorithm that includes PCT to monitor antibiotic choice and treatment duration will be addressed in prospective studies.

Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients

BRUNO, Benedetto
First
;
VALLERO, STEFANO GABRIELE;RAVIOLO, Stefania;CIGNETTI, Alessandro;AUDISIO, Ernesta;FESTUCCIA, MORENO BENEDETTO;CORCIONE, Silvia;BERGER, Massimo;SAGLIO, Francesco;MENGOZZI, GIULIO;DE ROSA, Francesco Giuseppe;GIACCONE, Luisa
2017

Abstract

Introduction: Febrile neutropenia (FN) represents a life-threatening complication in hematological malignancies. Its etiology is most often due to infections even though FN of other origins, such as tumor-related fever and non-infectious inflammation, should rapidly be ruled out. Initially, C-reactive protein and, more recently, procalcitonin (PCT) have been proposed as useful biomarkers for differential diagnosis. PCT was shown to be a good biomarker of bacterial infections and their clinical outcomes. Definition of standard cut-offs and design of PCT-guided treatment protocols remain however to be defined.Areas covered: In this review, highlights on the current clinical use of PCT and its potential role as a diagnostic tool have been discussed by a panel of physicians from different areas of expertise. We provide current clinical evidence that PCT has been shown to be a reliable biomarker to differentiate fever of bacterial origin from other causes. Moreover, the Authors convened to a round-table to discuss their real-life experience' and offer their recommendations by a Delphi survey.Expert commentary: PCT has an important clinical role in FN. Issues such as the validation of a specific decision algorithm that includes PCT to monitor antibiotic choice and treatment duration will be addressed in prospective studies.
10
6
543
550
Febrile neutropenia; hematological disease; hematopoietic stem cell transplantation; infections; procalcitonin; Biomarkers; C-Reactive Protein; Calcitonin; Diagnosis, Differential; Febrile Neutropenia; Humans; Hematology
Bruno, Benedetto; Busca, Alessandro; Vallero, Stefano; Raviolo, Stefania; Mordini, Nicola; Nassi, Luca; Cignetti, Alessandro; Audisio, Ernesta; Festuccia, Moreno; Corsetti, Alessandra; Depaoli, Lorella; Faraci, Maura; Micalizzi, Concetta; Corcione, Silvia; Berger, Massimo; Saglio, Francesco; Caropreso, Paola; Mengozzi, Giulio; Squadrone, Vincenzo; De Rosa, Francesco Giuseppe; Giaccone, Luisa
File in questo prodotto:
File Dimensione Formato  
PCT haematology Expert review Haem 2017 Bruno.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 651.16 kB
Formato Adobe PDF
651.16 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1647216
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 13
social impact